Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

IMPORTANCE: Treatment with atezolizumab plus bevacizumab may prolong overall survival among patients with unresectable hepatocellular carcinoma. However, to our knowledge, the cost-effectiveness of using this high-priced therapy for this indication is currently unknown. OBJECTIVE: To evaluate the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Dan, Wu, Bin, Shi, Lizheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905498/
https://www.ncbi.nlm.nih.gov/pubmed/33625508
http://dx.doi.org/10.1001/jamanetworkopen.2021.0037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905498/
https://www.ncbi.nlm.nih.gov/pubmed/33625508
http://dx.doi.org/10.1001/jamanetworkopen.2021.0037

Ejemplares similares